PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Blood

• Publication date

  2010-09-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/blood-2009-06-222943PMID 20505158PMCID PMC2938837
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies.

  2009cited by this paper
• SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

  2009cited by this paper
• Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model.

  2008cited by this paper
• CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

  2008cited by this paper
• Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma

  2008cited by this paper
• A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

  2008cited by this paper
• Diet, Autophagy, and Cancer: A Review

  2008cited by this paper
• Fenretinide induces autophagic cell death in caspase-defective breast cancer cells

  2008cited by this paper
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

  2007cited by this paper
• 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells

  2007cited by this paper
• Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer.

  2007cited by this paper
• Oridonin induced autophagy in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation.

  2007cited by this paper
• Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern

  2007cited by this paper
• The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

  2007cited by this paper
• Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

  2006cited by this paper
• hVps34 Is a Nutrient-regulated Lipid Kinase Required for Activation of p70 S6 Kinase*

  2005cited by this paper
• Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

  2005cited by this paper
• FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.

  2005cited by this paper
• Autophagy is a prosurvival mechanism in cells expressing an autosomal dominant familial neurohypophyseal diabetes insipidus mutant vasopressin transgene

  2005cited by this paper
• Proteasome Inhibition in the Treatment of Cancer

  2005cited by this paper
• The role of T-fimbrin in the response to DNA damage: silencing of T-fimbrin by small interfering RNA sensitizes human liver cancer cells to DNA-damaging agents.

  2005cited by this paper
• JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

  2004cited by this paper
• Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

  2004cited by this paper
• Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue.

  2004cited by this paper
• Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis

  2004cited by this paper
• Activated Gαq Inhibits p110α Phosphatidylinositol 3-Kinase and Akt*

  2003cited by this paper
• Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.

  2003cited by this paper
• Activated G alpha q inhibits p110 alpha phosphatidylinositol 3-kinase and Akt.

  2003cited by this paper
• Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells*

  2003cited by this paper
• Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

  2003cited by this paper
• Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

  2003cited by this paper
• Novel therapeutic approaches for multiple myeloma

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper
• Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.

  2002cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Novel therapies targeting the myeloma cell and its bone marrow microenvironment.

  2001cited by this paper
• The PI3K-PDK1 connection: more than just a road to PKB.

  2000cited by this paper
• Distinct Classes of Phosphatidylinositol 3′-Kinases Are Involved in Signaling Pathways That Control Macroautophagy in HT-29 Cells*

  2000cited by this paper
• Role of nitric oxide in the angiogenesis of avascular tissue.

  1999cited by this paper
• Prognostic factors in multiple myeloma.

  1999cited by this paper
• 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro.

  1998cited by this paper
• Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway

  1998cited by this paper
• Nutrient Deprivation of Cultured Rat Hepatocytes Increases the Desferrioxamine-available Iron Pool and Augments the Sensitivity to Hydrogen Peroxide*

  1997cited by this paper
• A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain

  1997cited by this paper
• The development of a model for the homing of multiple myeloma cells to human bone marrow.

  1997cited by this paper
• Prognostic factors in multiple myeloma

  1988cited by this paper

• Unraveling bortezomib resistance in multiple myeloma: insights from RNA-Seq and PI3K/mTOR pathway analysis

  2026cites this paper
• Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy

  2025cites this paper
• Fluorinated small molecule derivatives in cancer immunotherapy: emerging frontiers and therapeutic potential

  2025cites this paper
• Tumor microenvironment as a novel therapeutic target for lymphoid leukemias

  2025cites this paper
• Envelope protein-specific B cell receptors direct lentiviral vector tropism in vivo

  2024cites this paper
• PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma.

  2024cites this paper
• Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway

  2023cites this paper
• Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.

  2023cites this paper
• Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway

  2023cites this paper
• Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics

  2023cites this paper
• IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance

  2023cites this paper
• Tissue-specific identification of multi-omics features for pan-cancer drug response prediction

  2022cites this paper
• Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction

  2022cites this paper
• Pathogenic signaling in multiple myeloma.

  2022cites this paper
• Leukocytes mediate disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndrome

  2022cites this paper
• Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment

  2022cites this paper
• Autophagy in health and disease: From molecular mechanisms to therapeutic target

  2022cites this paper
• Current status of phosphoinotiside-3 kinase inhibitors in blood cancers

  2022cites this paper
• Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

  2021cites this paper
• Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma

  2021cites this paper
• Phosphatidylinositol 3-kinase signaling inhibitors for treatment of multiple myeloma: From small molecules to microRNAs

  2021cites this paper
• SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta

  2021cites this paper
• PI3K inhibitors are finally coming of age

  2021cites this paper
• Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis

  2021cites this paper
• A Structural Approach into Drug Discovery Based on Autophagy

  2021cites this paper
• Autophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions

  2021cites this paper
• Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy

  2021cites this paper
• Class I PI3K Provide Lipid Substrate in T Cell Autophagy Through Linked Activity of Inositol Phosphatases

  2021cites this paper
• Leukocyte proliferation mediates disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndrome

  2021cites this paper
• Exploring the selective mechanism of inhibitors towards different subtypes of class I PI3K

  2021cites this paper
• Current Treatment Options in CLL

  2021cites this paper
• Inhibitory effect of PI3Kδ inhibitor idelalisib on proliferation of human myeloid leukemia cells and the reversal effect on drug resistance to adriamycin.

  2020cites this paper
• MODULAÇÃO DA AUTOFAGIA COMO ESTRATÉGIA TERAPÊUTICA CONTRA O CÂNCER

  2020cites this paper
• Autism Spectrum Disorder: Signaling Pathways and Prospective Therapeutic Targets

  2020cites this paper
• Targeting Autophagy In Disease: Recent Advances In Drug Discovery

  2020cites this paper
• Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells

  2020cites this paper
• Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma.

  2019cites this paper
• Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.

  2019cites this paper
• The Value of Anti-angiogenics in Multiple Myeloma Therapy

  2019cites this paper
• Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade

  2019cites this paper
• Chapter 2 The CLL Cell Microenvironment

  2019cites this paper
• Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms

  2019cites this paper
• Vincamine as a GPR40 agonist improves glucose homeostasis in type 2 diabetic mice.

  2019cites this paper
• 2,4-Dihydroxy-3′-methoxy-4′-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K/akt/mTOR signaling pathway

  2019cites this paper
• New roles for B cell receptor associated kinases: when the B cell is not the target

  2019cites this paper
• Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth

  2019cites this paper
• The B‐cell receptor in control of tumor B‐cell fitness: Biology and clinical relevance

  2019cites this paper
• INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies

  2018cites this paper
• The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

  2018cites this paper
• Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.

  2018cites this paper
• Idelalisib.

  2018cites this paper
• Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.

  2018cites this paper
• Phosphatidylinositol 3-kinase p110δ expression in Merkel cell carcinoma

  2018cites this paper
• The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

  2018cites this paper
• Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

  2018cites this paper
• Investigations into the protective effects of the Multiple Myeloma Bone Marrow Microenvironment

  2018influential citation
• The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells

  2018cites this paper
• Mechanisms of Resistance in Multiple Myeloma.

  2018cites this paper
• Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance

  2017cites this paper
• The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.

  2017cites this paper
• A p110δ-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-κB.

  2017cites this paper
• Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis

  2017cites this paper
• The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.

  2017cites this paper
• Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview

  2017cites this paper
• Chapter 26 – Idelalisib

  2017cites this paper
• PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment

  2017cites this paper
• Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia

  2017cites this paper
• The Class I PI3K inhibitor S14161 induces autophagy in malignant blood cells by modulating the Beclin 1/Vps34 complex.

  2017cites this paper
• Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.

  2017cites this paper
• The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma

  2017cites this paper
• Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion.

  2017cites this paper
• Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors.

  2016cites this paper
• Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma

  2016cites this paper
• Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances

  2016cites this paper
• PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.

  2016cites this paper
• MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy

  2016cites this paper
• Expression of the phosphoinositide 3-kinase p 110 δ isoform and its clinicopathological significance in gastric cancer

  2016cites this paper
• Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance

  2016cites this paper
• Kinase inhibitors as potential agents in the treatment of multiple myeloma

  2016cites this paper
• Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen

  2016cites this paper
• RNA interference for multiple myeloma therapy: targeting signal transduction pathways

  2016cites this paper
• High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib

  2016cites this paper
• Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma

  2016cites this paper
• Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.

  2015cites this paper
• Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms

  2015cites this paper
• The critical role of Akt in cardiovascular function.

  2015cites this paper
• Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress.

  2015cites this paper
• Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma

  2015cites this paper
• Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth

  2015cites this paper
• Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms

  2015cites this paper
• Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib

  2015cites this paper
• Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs

  2015cites this paper
• Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach

  2015cites this paper
• Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia

  2015cites this paper
• Novel therapeutic strategies for multiple myeloma.

  2015cites this paper
• Techniques for the discovery of selective inhibitors of phosphatidylinositol 3-kinase for the treatment of hematological malignancies

  2015cites this paper
• The tumor microenvironment shapes hallmarks of mature B-cell malignancies

  2015cites this paper
• The Guareschi Pyridine Scaffold as a Valuable Platform for the Identification of Selective PI3K Inhibitors

  2015cites this paper
• Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells

  2015influential citation
• Idelalisib for the treatment of B-cell malignancies

  2015cites this paper